NEW YORK (TheStreet) -- The major U.S. equity averages finished modestly lower Monday with sentiment soured by frustration with the efforts of European leaders to address the region's debt crisis.
was also an uncharacteristically weak spot with the stock falling back below $700 as Wall Street was unimpressed with news the company sold more than 5 million iPhone 5s over the weekend.
Dow Jones Industrial Average
lost nearly 21 points, or 0.15%, to close at 13,559. The blue-chip index is still up roughly 11% so far in 2012.
Breadth was negative with decliners outpacing advancers, 18 to 11 with
finishing flat. The biggest percentage decliners in the Dow were
Blue-chip gainers included
Shares of health insurance company
slipped in its first day of trading as part the Dow after replacing
, which is splitting into two entities.
fell more than 3 points, or 0.22%, to settle at 1457, while the
dropped more than 19 points, or 0.60%, to close at 3161.
Sales of the iPhone 5 may be running better than the iPhone 4S, but
The news prompted a 1.3% drop in Apple shares on heavier than normal volume.
The weakest sectors in the broad market were technology, basic materials and consumer cyclicals. Transportation and utilities were the only areas of strength. Volume totaled 2.99 billion on the New York Stock Exchange and 1.70 billion on the Nasdaq.
"Many of the short-term momentum indicators are still in 'overbought territory' -- meaning further corrective action is likely in the weeks ahead," said Paul Nolte, managing director at Dearborn Partners.
"This would be in line with a normal 'bad' October; however the Fed actions should keep any correction relatively mild. This scenario fits very neatly into a seasonally weak period and sets up for a nice year-end rally," he continued.
The market mood was soured Monday by reports that Germany and France were clashing on the timeline for introducing a banking union with German Chancellor Angela Merkel wanting to move at a much more measured pace and French President Francois Hollande urging quicker action.
Meanwhile, speculation arose that Greece's budget shortfall was a lot greater than previously expected, though the Greek Ministry of Finance refuted the reports.
The nervous atmosphere was also being fed by data showing that the German Ifo index of business confidence unexpectedly declined this month, and a CBB International report indicating that optimism among Chinese manufacturers and retailers about sales has dimmed compared with three months ago.
Over the weekend, a People's Bank of China official warned that the country's slowing economy could extend into next year.
A dearth of guidance from Spain on its bailout plans also added to the global anxiety.
In addition, Standard & Poor's lowered its full-year economic growth outlook for the Asia Pacific region. At home, the general business activity index from the Dallas Fed Manufacturing Survey remained slightly negative but edged up to -0.9 from -1.6, and the Chicago Fed National Activity Index decreased to -0.87 in August from -0.12 in July led by declines in production-related indicators.
The FTSE in London closed down 0.24% and the DAX in Germany settled off 0.52%. Hong Kong's Hang Seng index finished down by 0.19% on Monday and the Nikkei in Japan settled behind by 0.45%.
The benchmark 10-year Treasury gained 13/32, pushing the yield down to 1.711%. The greenback rose 0.20%, according to the
November crude oil futures lost 96 cents to settle at $91.93 a barrel while December gold futures dropped $13.40 to settle at $1,764.60 an ounce.
In corporate news,
shares dropped more than 9% after
over the weekend.
, the homebuilder, posted fiscal third-quarter earnings of 40 cents a share. Revenue in the quarter rose 34% to $1.1 billion. Shares lost 1.5%.
shares hit an all-time intraday high at $747.28 after
noted that the internet giant's streamlining of its Motorola Mobility business was grabbing the attention of the investment community. Shares popped 2.1% at final check.
shares tumbled 36.7% after saying that the company is under a U.S. government investigation involving its promotional practices and that the firm plans to cooperate in the process.
shares plunged 78.5% after the company said that it discovered major discrepancies between some patient sample test results and patient treatment code assignments during the course of preparing for a meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase 2 trial of bavituximab in second-line non-small cell lung cancer.
2012 Stock Predictions and Outlook
--Written by Andrea Tse and Joe Deaux in New York.
>To contact the writer of this article, click here: